|
BAICALEIN |
|
5,6,7-Trihydroxy-2-phenyl-4H-1-benzopyran-4-one; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; |
|
|
| PRODUCT IDENTIFICATION |
|
|
CAS RN |
491-67-8 (Base); 23615-79-4 (Phosphate) |
|
EINECS RN |
|
|
FORMULA |
C15H10O5 |
|
MOLE WEIGHT |
270.24 |
|
CHEMICAL FAMILY |
Flavone |
|
CLASSIFICATION |
Astringent; Enzyme inhibitor; Antioxidant; Prostaglandin Antagonis; Free Radical Scavenger; |
|
|
| PHYSICAL AND CHEMICAL PROPERTIES |
|
|
PHYSICAL STATE |
white to pale-yellow solid |
|
MELTING POINT |
264 - 265 C |
|
BOILING POINT |
|
|
DENSITY |
|
|
SOLUBILITY IN WATER |
Insoluble |
|
pH |
|
|
VAPOR DENSITY |
|
|
REFRACTIVE INDEX |
|
|
FLASH POINT |
|
|
|
| STABILITY AND REACTIVITY | |
| STABILITY | Stable under normal conditions |
|
INCOMPATIBILITIES |
Strong oxidizing agents |
| DECOMPOSITION PRODUCTS |
Carbon oxides |
| POLYMERIZATION | |
|
TOXICOLOGICAL |
|
|
|
|
POTENTIAL HEALTH EFFECTS |
|
|
HAZARD OVERVIEW |
|
|
EYE |
Causes eye irritation. |
|
SKIN |
May be harmful if absorbed through skin. May cause skin irritation. |
|
INGESTION |
May be harmful if swallowed. |
|
INHALATION |
May be harmful if inhaled. May cause respiratory tract irritation. |
| TARGET ORGANS |
|
|
|
| TRANSPORT & REGULATORY INFORMATION |
|
|
UN NO. |
|
| HAZARD CLASS |
XI |
| PACKING GROUP |
|
| HAZARD SYMBOL |
|
|
RISK PHRASES |
36/37/38 |
|
SAFETY PHRASES |
26-36 |
|
|
| EXTERNAL LINKS & GENERAL INFORMATION | |
|
Wikipedia Linking: http://en.wikipedia.org/wiki/Baicalein Baicalein, one of the major flavonoids contained in the dried roots, possesses a multitude of pharmacological activities. The glycoside of baicalein, baicalin is a potent anti-inflammatory and anti-tumor agent. This review describes the biological properties of baicalein (Table 1), which are associated with the prevention and treatment of cardiovascular diseases. Baicalein is a potent free radical scavenger and xanthine oxidase inhibitor, thus improving endothelial function and conferring cardiovascular protective actions against oxidative stress-induced cell injury. Baicalein lowers blood pressure in renin-dependent hypertension and the in vivo hypotensive effect may be partly attributed to its inhibition of lipoxygenase, resulting in reduced biosynthesis and release of arachidonic acid-derived vasoconstrictor products. On the other hand, baicalein enhances vasoconstricting sensitivity to receptor-dependent agonists such as noradrenaline, phenylephrine, serotonin, U46619 and vasopressin in isolated rat arteries. The in vitro effect is likely caused by inhibition of an endothelial nitric oxide-dependent mechanism. The anti-thrombotic, anti-proliferative and anti-mitogenic effects of the roots of S. baicalensis and baicalein are also reported. Baicalein inhibits thrombin-induced production of plasminogen activator inhibitor-1, and interleukin-1beta- and tumor necrosis factor-alpha-induced adhesion molecule expression in cultured human umbilical vein endothelial cells. The pharmacological findings have highlighted the therapeutic potentials of using plant-derived baicalein and its analogs for the treatment of arteriosclerosis and hypertension. (http://www.ncbi.nlm.nih.gov/)The active ingredients of ‘golden root’ of Scutellaria baicalensis GEORGI (Huang-Qin), a valuable traditional Chinese medicine, are polyhydroxyflavonoids, namely baicalein, oroxylin A and wogonin. With the objective of overcoming their poor solubility and to investigate their structure and activity relationships, baicaleinyl 7-O-sulfate was prepared, and extensive comparative antioxidative and anti-inflammatory tests were conducted. All the polyhydroxyflavonoids exhibited significant antioxidative and free-radical scavenging activities. In respect of their nitric oxide (NO) inhibition, wogonin was superior to all the other flavonoids, while oroxylin A was most potent in the inhibition of lipid peroxidation. Wogonin proved to be the most potent (82.9% inhibition, p<0.05) in its anti-inflammatory activity against carrageenan-induced rat hind paw edema. There was a correlation between the in-vivo anti-inflammatory activity and the in-vitro antioxidative activities. (http://ci.nii.ac.jp/) |
|
|
| SALES SPECIFICATION |
|
|
APPEARANCE |
white to pale-yellow solid |
|
CONTENT |
98% min (HPLC) |
|
PARTICLE SIZE |
80 mesh (100%) |
| RESIDUE ON IGNITION |
1.0% max |
|
RESIDUAL SOLVENTS |
EU2000 |
|
HEAVY METALS |
20ppm max |
|
ARSENIC |
2ppm max |
|
LOSS ON DRYING |
3.0% max |
| MICROBIOLOGY |
Aerobic Plate Count: 100 organisms/g max |
|
|
| PRICE |
 |
